

PROBI AB

INTERIM REPORT JANUARY - SEPTEMBER 2009

Launch of new probiotic juice with Skånemejerier

- **Net sales** for the interim period amounted to 49.7 million SEK (52.2) and to 14.3 million SEK (16.5) for the third quarter.
- **EBIT** for the interim period amounted to 12.0 million SEK (7.8) and to 3.1 million SEK (2.9) for the third quarter, an increase of 55 percent for the interim period.
- **Profit after tax** for the interim period amounted to 9.3 million SEK (6.6) and to 2.1 million SEK (2.5) for the third quarter.
- **Earnings per share** for the interim period amounted to 1.00 SEK (0.71) and to 0.23 SEK (0.26) for the third quarter.
- **Cash flow** for the interim period amounted to 11.6 million SEK (8.3) and to 2.5 million SEK (2.7) for the third quarter.
- A new probiotic juice with positive effects on the immune system was launched during the third quarter together with Skånemejerier.
- ProViva sales continues to develop positively.
- Probi forecasts EBIT and cash flow to be positive during 2009.

CEO's COMMENTS:

"It is pleasing to, together with Skånemejerier, so quickly be able to turn our research into a new product such as Bravo Friscus. It is the world's first probiotic juice with clinically proven effects on common cold symptoms and the immune system. In the long run we see the possibility for Bravo Friscus to develop in the same way as ProViva," says Michael Oredsson, CEO of Probi.

FOR FURTHER INFORMATION, CONTACT:

Michael Oredsson, CEO, Probi, phone: +46 (0)46 286 89 23 or +46 (0)707 18 89 30
e-mail: michael.oredsson@probi.se

Distributed Oct. 21st, 2009, 09.30 (CET)

ABOUT PROBI

Probi is a leading player in the field of probiotic research and development of effective and well-documented probiotics. The research areas are: stomach and gastrointestinal tracts, immune defense, metabolic disorders as well as stress and recovery. Probi's customers are leading companies within the business areas Functional Food and Dietary Supplements. The company's total operating income was 69.4 million SEK 2008, consisting mostly of royalty revenues. Probi's shares are listed on the Nordic List of the Stockholm Stock Exchange, Small Cap and has approximately 4.500 shareholders. Visit www.probi.com.

